

# Are unclear scans delaying the care your patients need?

Repeat testing, unnecessary procedures, or missed diagnoses could lead to delays in care and undue patient stress.



**See how cardiac PET scans with  
Flyrcado™ (Flurpiridaz F 18)  
sharpen the picture of known  
or suspected coronary artery  
disease (CAD) cases\***



\*Relative to SPECT

Please see the back panel for Flyrcado Important Safety Information and the full Prescribing Information.

# When results are unclear, patients pay the price


Cardiac PET MPI provides additional diagnostic certainty over SPECT that helps optimize downstream testing<sup>1</sup> and improve care confidence—particularly in patients who are challenging to image, such as those with<sup>2-4</sup>:

- ✓ High BMI >30
- ✓ Large or dense breast tissue
- ✓ Multivessel disease
- ✓ Diabetes



Clinical insight	Key evidence
Diagnostic confidence	96% definitive diagnosis with PET vs. 82% with SPECT. <sup>5</sup>
Fewer unnecessary downstream procedures	Among patients with suspected CAD, PET required <b>fewer downstream healthcare resources (25–37%) than SPECT MPI (40–49%).</b> <sup>6</sup>
Radiation and efficiency	PET offers distinct advantages over SPECT, including lower radiation dose, shorter procedure time, and dynamic imaging capability. With <sup>18</sup> F-flurpiridaz, patients can be reimaged during the same appointment without additional dosing or radiation exposure.

Clearer images.  
**Confident**  
next steps.



# Flyrcado expands PET access<sup>4,7,8</sup> and flexibility<sup>4,9</sup>



## Regional radiopharmacy distribution

Removes the need for an on-site generator or cyclotron<sup>4,10</sup>—making PET more accessible for your patients and easier to schedule locally.<sup>4,7,8</sup>



## High spatial resolution

Supports clarity in patients with obesity or diabetes, helping you interpret results with greater confidence—especially in populations where SPECT images can be less reliable.<sup>5</sup>



## 109-minute half-life

Allows either exercise or pharmacologic stress testing, giving you flexibility to choose the most clinically appropriate option for each patient.<sup>4,9</sup>



## Coverage and claims support

Backed by dedicated claims experts, your team can navigate billing, coding, and coverage with confidence.



See how clarity in Joe's case *changed care decisions.*

*The image shown is a model and not a real patient.*

## Clinical case: Living with a heart transplant, Joe needed certainty

*75-year-old man with diabetes and high cholesterol*

- Avid golfer, 10 years post-heart transplant
- Initial SPECT scan was inconclusive due to subdiaphragmatic artifact obscuring the inferior wall
- PET MPI with Flyrcado™ delivered clear, preserved image quality despite the artifact
- Rest and stress scans showed uniform perfusion → no ischemia



**PET ruled out cardiac allograft vasculopathy with certainty, giving Joe and his care team confidence to move forward.**

## These are the sites near you that offer cardiac PET with Flyrcado:



Scan the QR code to access the Flyrcado Patient Referral Form

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2, then option 1) or by e-mail at [GPV.drugsafety@gehealthcare.com](mailto:GPV.drugsafety@gehealthcare.com) or FDA at 800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### IMPORTANT SAFETY INFORMATION

#### FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use

##### Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

##### Contraindications

None

##### Radiation Risks

- FLYRCADO contributes to cumulative radiation exposure, which is associated with an increased risk of cancer.
- Handle safely to minimize exposure for patients and staff.
- Advise patients to hydrate before and after administration and to void frequently.

##### Adverse Reactions

- Most common adverse reactions ( $\geq 2\%$ ) include dyspnea, headache, angina pectoris, chest pain, fatigue, ST-segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

##### Use in Specific Populations

**Pregnancy:** No human data are available. Counsel patients about potential fetal risks related to radiation and ethanol exposure (contains up to 337 mg anhydrous ethanol).

**Lactation:** Advise women to pump and discard breast milk for at least 8 hours after administration.

**Pediatric Use:** Safety and effectiveness have not been established.

### References:

1. Fisher J, et al. Does cardiac PET myocardial perfusion imaging in a clinical practice change referral for cardiac catheterization? Bryn Mawr Medical Specialists Association. Accessed October 3, 2025. [https://www.mismedical.com/wp-content/uploads/2024/07/ASNC\\_MISMedical\\_BrynMawr-Final.pdf](https://www.mismedical.com/wp-content/uploads/2024/07/ASNC_MISMedical_BrynMawr-Final.pdf)
2. Schindler TH, Bateman TM, Berman DS, et al. Appropriate use criteria for PET myocardial perfusion imaging. *J Nucl Med.* 2020;61(8):1221-1265.
3. Bateman TM, Dilsizian V, Beanlands RS, DePuey EG, Heller GV, Wolinsky DA. American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET. *J Nucl Med.* 2016;57(10):1654-1656.
4. Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. *Curr Cardiol Rep.* 2022;24(8):987-994.
5. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial perfusion imaging in patients with suspected coronary artery disease. *J Am Coll Cardiol.* 2023;82(16):1598-1610.
6. Pelletier-Galarneau M, Cabra A, Szabo E, Angadageri S. Real-world evidence study on the impact of SPECT MPI, PET MPI, cCTA and stress echocardiography on downstream healthcare utilisation in patients with coronary artery disease in the US. *BMC cardiovascular disorders.* 2024;24(1):543. doi:<https://doi.org/10.1186/s12872-024-04225-y>
7. Driessen RS, Rajmakers PG, Stuijzand WJ, Knaapen P. Myocardial perfusion imaging with PET. *Int J Cardiovasc Imaging.* 2017;33(7):1021-1031.
8. Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. *J Am Coll Cardiol.* 2023;82(16):1611-1613.
9. Flyrcado (flurpiridaz F 18 injection). Full Prescribing Information. Marlborough, MA: GE HealthCare.
10. Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. *Semin Nucl Med.* 2014;44(5):333-343.



Scan the QR code to view full Prescribing Information.

© 2025 GE HealthCare  
Flyrcado is a trademark of GE HealthCare.  
GE is a trademark of General Electric Company used under trademark license. December 2025 | JB12785US